UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration
19. September 2022 08:00 ET
|
Unity Biotechnology, Inc.
Enrollment of 51 patients exceeds target by ~10% due to high interest in the study 16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif., Sept. 19,...